Table 1.

Associations of TMEFF2 methylation with the clinicopathological features of NSCLC patients

Feature	Methylation frequency (%)	Crude			Adjusted
		OR	95% CI	pa	OR	95% CI	pb
All subjects (n = 139)	73 (52.5)
Age (years)
≤ 62 (n = 60)	34 (56.7)	1.00			1.00
→ 62 (n = 79)	39 (49.4)	0.75	0.38–1.46	0.40	0.77	0.38–1.56	0.46
Gender
Male (n = 101)	48 (47.5)	1.00			1.00
Female (n = 38)	25 (65.8)	2.12	0.98–4.61	0.06	1.93	0.47–7.82	0.36
Smoking status
Ever (n = 104)	50 (48.1)	1.00			1.00
Never (n = 35)	23 (65.7)	2.07	0.93–4.59	0.07	1.48	0.34–6.41	0.60
Histology types
SCC (n = 60)	32 (53.3)	1.00			1.00
AC (n = 79)	41 (51.9)	0.944	0.48–1.85	0.87	0.62	0.28–1.34	0.23
Pathologic stages
Stage I (n = 85)	46 (54.1)	1.00			1.00
Stage II–IIIA (n = 54)	27 (50.0)	0.85	0.43–1.68	0.64	0.79	0.38–1.61	0.51
EGFR mutation in ACs
Present (n = 33)	12 (36.4)	1.00			1.00
Absent (n = 46)	29 (63.0)	2.99	1.18–7.55	0.02	7.13	2.05–24.83	0.002

^aP-value was calculated by the logic regression test.

^bP-value was calculated by the logic regression test adjusted for other variables.

SCC, squamous cell carcinoma; AC, adenocarcinoma; OR, odds ratio; CI, confidence interval